Every peptide, traced from the lab where it was first synthesized to the researcher who uses it today.
Click any country to see what peptide work originated there. Pick a peptide to follow its journey across the globe — discovery, manufacturing, sourcing, clinical use — as kinetic arcs.
Peptide register
Select to trace journey
A century of peptide synthesis, one origin at a time.
Each marker is the first published synthesis of a catalogued peptide.
BPC-157
Body Protection Compound · pentadecapeptide · MW 1419 Da
A 15-amino-acid sequence drawn from a fragment of body protection compound found in gastric juice. Characterized at the University of Zagreb by Predrag Sikiric's research group throughout the 1990s and 2000s. The entire BPC-157 literature traces back to this single Croatian insti…
Open the BPC-157 entry- 01HRV·1991
- 02CHN·ongoing
- 03KOR·ongoing
- 04USA·ongoing
Five countries account for most peptide origins.
The first chemical synthesis of a peptide rarely happens twice. Each peptide has a single origin lab, and a handful of countries concentrate the discovery work — even as today's manufacturing chains route through different geography.
All catalogued countries →Peer-reviewed publication, Nobel records, or institutional historical archives. Multi-attributed where the literature splits.
Industry-typical roles at country granularity — never specific suppliers or batches.
The editorial team earns a referral fee on sourcing notes routed to revialife.com. Disclosed on every peptide panel.
Common questions.
- Where do the origin claims come from?
- Every origin entry traces to peer-reviewed publication, Nobel records, or institutional historical archives. Where the literature splits across multiple institutions or years, each contributor is attributed separately. The methodology page lists the editorial standard in detail.
- Why do so many peptides route through China and Korea on the journey arcs?
- Because that's where most large-scale research-peptide manufacturing happens today. China's Hangzhou and Suzhou clusters and Korea's Anyang and Daejeon GMP facilities produce the bulk of research-grade peptide API shipped globally. The journey stops describe these industry-typical routes at country granularity — not specific suppliers or batches.
- Is this atlas affiliated with a supplier?
- The editorial team earns a referral fee when peptide-panel sourcing notes route a reader to revialife.com. The disclosure is on every peptide panel that carries such a note. The atlas itself is editorial — origins, contributors, journeys, and citations are independent of the commercial relationship.
Every peptide has a place of origin. Some were isolated from animal tissue a century ago. Some were designed by a team of medicinal chemists at a specific institution in a specific year. All of them now move through a manufacturing supply chain — typically routed through Switzerland, China, Korea, or India — before arriving at the lab where the research actually happens.
This atlas exists because most peptide reference material on the open web omits these origins entirely. The compound shows up in a catalog with a price and a purity figure, and the chain of discovery and manufacture behind it is invisible. Restoring the chain is editorial work — it doesn't change the chemistry, but it makes the chemistry legible.